Overexpression of PCBP2 contributes to poor prognosis and enhanced cell growth in human hepatocellular carcinoma
Poly(C)-binding protein 2 (PCBP2) is a member of the PCBP family, and plays an important role in post-transcriptional and translational regulation of various signaling molecules through direct binding to single-stranded poly(C) motifs. PCBP2 has been reported to play a critical role in the developme...
Gespeichert in:
| Veröffentlicht in: | Oncology reports 2016-12, Vol.36 (6), p.3456-3464 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3464 |
|---|---|
| container_issue | 6 |
| container_start_page | 3456 |
| container_title | Oncology reports |
| container_volume | 36 |
| creator | Zhang, Xiubing Hua, Lu Yan, Daliang Zhao, Fengbo Liu, Jinxia Zhou, Huiling Liu, Jie Wu, Miaomiao Zhang, Chengliang Chen, Yingying Chen, Buyou Hu, Baoying |
| description | Poly(C)-binding protein 2 (PCBP2) is a member of the PCBP family, and plays an important role in post-transcriptional and translational regulation of various signaling molecules through direct binding to single-stranded poly(C) motifs. PCBP2 has been reported to play a critical role in the development of multiple human tumors. However, whether PCBP2 participates in hepatocellular carcinoma (HCC) development remains largely elusive. Herein, we showed that PCBP2 was upregulated in human HCC tissues and cell lines. Overexpression of PCBP2 predicted significantly worsened prognosis in HCC patients, suggesting that PCBP2 may serve as a prognostic marker of HCC. In addition, we found that depletion of PCBP2 inhibited HCC cell proliferation, accompanying the increase in the cyclin-dependent kinase inhibitor p27 level. Moreover, we found that high expression of PCBP2 may contribute to sorafenib resistance in HCC cells, involving dysregulated expression of Bax and Bcl-2 proteins. In conclusion, our results suggest that PCBP2 may serve as a prognostic marker and potential therapeutic target of HCC. |
| doi_str_mv | 10.3892/or.2016.5167 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1835444004</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A479407089</galeid><sourcerecordid>A479407089</sourcerecordid><originalsourceid>FETCH-LOGICAL-c513t-afab4cf46175179e8fedaeea6e44a47aa21bf3e16653777dbd40abcf03aa67783</originalsourceid><addsrcrecordid>eNpdkUtv1TAQRiMEoqWwY40sISEW5GLHjp0sy1V5SJXaBUjsrIkzuUmVeIKdFPrvcdTSAhuPJR_NfOOTZS8F38mqLt5T2BVc6F0ptHmUHQtTi7xQUjxOd16IXMry-1H2LMYrzgvDdf00OyqMUVUtyuNsvrjGgL_mgDEO5Bl17HL_4bJgjvwShmZdMLKF2EwU2Bzo4CkOkYFvGfoevMOWORxHdgj0c-nZ4Fm_TpBOnGGh7WkdITAHwQ2eJniePelgjPjirp5k3z6efd1_zs8vPn3Zn57nrhRyyaGDRrlOaWHKtBJWHbaACBqVAmUACtF0EoXWpTTGtE2rODSu4xJAG1PJk-ztbd8U-seKcbHTELc44JHWaEUlS6UU5yqhr_9Dr2gNPqWzopaFNqouzQN1gBHt4DtaAritqT1Vplbc8KpO1Ju_qB5hXPpI47qkz43_gu9uQRcoxoCdncMwQbixgttNrKVgN7F2E5vwV3cZ12bC9h7-Y_JhcJyTnKGleM9QyKXOuc6lKrX8Dby2qq8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1932674957</pqid></control><display><type>article</type><title>Overexpression of PCBP2 contributes to poor prognosis and enhanced cell growth in human hepatocellular carcinoma</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Zhang, Xiubing ; Hua, Lu ; Yan, Daliang ; Zhao, Fengbo ; Liu, Jinxia ; Zhou, Huiling ; Liu, Jie ; Wu, Miaomiao ; Zhang, Chengliang ; Chen, Yingying ; Chen, Buyou ; Hu, Baoying</creator><creatorcontrib>Zhang, Xiubing ; Hua, Lu ; Yan, Daliang ; Zhao, Fengbo ; Liu, Jinxia ; Zhou, Huiling ; Liu, Jie ; Wu, Miaomiao ; Zhang, Chengliang ; Chen, Yingying ; Chen, Buyou ; Hu, Baoying</creatorcontrib><description>Poly(C)-binding protein 2 (PCBP2) is a member of the PCBP family, and plays an important role in post-transcriptional and translational regulation of various signaling molecules through direct binding to single-stranded poly(C) motifs. PCBP2 has been reported to play a critical role in the development of multiple human tumors. However, whether PCBP2 participates in hepatocellular carcinoma (HCC) development remains largely elusive. Herein, we showed that PCBP2 was upregulated in human HCC tissues and cell lines. Overexpression of PCBP2 predicted significantly worsened prognosis in HCC patients, suggesting that PCBP2 may serve as a prognostic marker of HCC. In addition, we found that depletion of PCBP2 inhibited HCC cell proliferation, accompanying the increase in the cyclin-dependent kinase inhibitor p27 level. Moreover, we found that high expression of PCBP2 may contribute to sorafenib resistance in HCC cells, involving dysregulated expression of Bax and Bcl-2 proteins. In conclusion, our results suggest that PCBP2 may serve as a prognostic marker and potential therapeutic target of HCC.</description><identifier>ISSN: 1021-335X</identifier><identifier>EISSN: 1791-2431</identifier><identifier>DOI: 10.3892/or.2016.5167</identifier><identifier>PMID: 27748915</identifier><language>eng</language><publisher>Greece: D.A. Spandidos</publisher><subject>Adult ; Aged ; Alcohol ; Antineoplastic Agents - pharmacology ; Binding proteins ; Cancer therapies ; Carcinoma, Hepatocellular - metabolism ; Carcinoma, Hepatocellular - mortality ; Carcinoma, Hepatocellular - pathology ; Care and treatment ; Cell cycle ; Cell growth ; Cell Line, Tumor ; Cell Proliferation ; Chemotherapy ; Development and progression ; Drug resistance ; Drug Resistance, Neoplasm ; Female ; Gene Expression ; Genetic aspects ; Health aspects ; hepatocellular carcinoma ; Hepatoma ; Humans ; Inhibitor drugs ; Inhibitory Concentration 50 ; Kaplan-Meier Estimate ; Liver cancer ; Liver Neoplasms - metabolism ; Liver Neoplasms - mortality ; Liver Neoplasms - pathology ; Male ; Medical prognosis ; Metastasis ; Methods ; Middle Aged ; Molecular targeted therapy ; Multivariate analysis ; Niacinamide - analogs & derivatives ; Niacinamide - pharmacology ; Patients ; Phenylurea Compounds - pharmacology ; poly(C)-binding protein 2 ; Prognosis ; Proteins ; RNA-Binding Proteins - genetics ; RNA-Binding Proteins - metabolism ; sorafenib resistance ; Surgery ; Tumors ; Young Adult</subject><ispartof>Oncology reports, 2016-12, Vol.36 (6), p.3456-3464</ispartof><rights>Copyright © 2016, Spandidos Publications</rights><rights>COPYRIGHT 2016 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c513t-afab4cf46175179e8fedaeea6e44a47aa21bf3e16653777dbd40abcf03aa67783</citedby><cites>FETCH-LOGICAL-c513t-afab4cf46175179e8fedaeea6e44a47aa21bf3e16653777dbd40abcf03aa67783</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27748915$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Xiubing</creatorcontrib><creatorcontrib>Hua, Lu</creatorcontrib><creatorcontrib>Yan, Daliang</creatorcontrib><creatorcontrib>Zhao, Fengbo</creatorcontrib><creatorcontrib>Liu, Jinxia</creatorcontrib><creatorcontrib>Zhou, Huiling</creatorcontrib><creatorcontrib>Liu, Jie</creatorcontrib><creatorcontrib>Wu, Miaomiao</creatorcontrib><creatorcontrib>Zhang, Chengliang</creatorcontrib><creatorcontrib>Chen, Yingying</creatorcontrib><creatorcontrib>Chen, Buyou</creatorcontrib><creatorcontrib>Hu, Baoying</creatorcontrib><title>Overexpression of PCBP2 contributes to poor prognosis and enhanced cell growth in human hepatocellular carcinoma</title><title>Oncology reports</title><addtitle>Oncol Rep</addtitle><description>Poly(C)-binding protein 2 (PCBP2) is a member of the PCBP family, and plays an important role in post-transcriptional and translational regulation of various signaling molecules through direct binding to single-stranded poly(C) motifs. PCBP2 has been reported to play a critical role in the development of multiple human tumors. However, whether PCBP2 participates in hepatocellular carcinoma (HCC) development remains largely elusive. Herein, we showed that PCBP2 was upregulated in human HCC tissues and cell lines. Overexpression of PCBP2 predicted significantly worsened prognosis in HCC patients, suggesting that PCBP2 may serve as a prognostic marker of HCC. In addition, we found that depletion of PCBP2 inhibited HCC cell proliferation, accompanying the increase in the cyclin-dependent kinase inhibitor p27 level. Moreover, we found that high expression of PCBP2 may contribute to sorafenib resistance in HCC cells, involving dysregulated expression of Bax and Bcl-2 proteins. In conclusion, our results suggest that PCBP2 may serve as a prognostic marker and potential therapeutic target of HCC.</description><subject>Adult</subject><subject>Aged</subject><subject>Alcohol</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Binding proteins</subject><subject>Cancer therapies</subject><subject>Carcinoma, Hepatocellular - metabolism</subject><subject>Carcinoma, Hepatocellular - mortality</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Care and treatment</subject><subject>Cell cycle</subject><subject>Cell growth</subject><subject>Cell Line, Tumor</subject><subject>Cell Proliferation</subject><subject>Chemotherapy</subject><subject>Development and progression</subject><subject>Drug resistance</subject><subject>Drug Resistance, Neoplasm</subject><subject>Female</subject><subject>Gene Expression</subject><subject>Genetic aspects</subject><subject>Health aspects</subject><subject>hepatocellular carcinoma</subject><subject>Hepatoma</subject><subject>Humans</subject><subject>Inhibitor drugs</subject><subject>Inhibitory Concentration 50</subject><subject>Kaplan-Meier Estimate</subject><subject>Liver cancer</subject><subject>Liver Neoplasms - metabolism</subject><subject>Liver Neoplasms - mortality</subject><subject>Liver Neoplasms - pathology</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Methods</subject><subject>Middle Aged</subject><subject>Molecular targeted therapy</subject><subject>Multivariate analysis</subject><subject>Niacinamide - analogs & derivatives</subject><subject>Niacinamide - pharmacology</subject><subject>Patients</subject><subject>Phenylurea Compounds - pharmacology</subject><subject>poly(C)-binding protein 2</subject><subject>Prognosis</subject><subject>Proteins</subject><subject>RNA-Binding Proteins - genetics</subject><subject>RNA-Binding Proteins - metabolism</subject><subject>sorafenib resistance</subject><subject>Surgery</subject><subject>Tumors</subject><subject>Young Adult</subject><issn>1021-335X</issn><issn>1791-2431</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNpdkUtv1TAQRiMEoqWwY40sISEW5GLHjp0sy1V5SJXaBUjsrIkzuUmVeIKdFPrvcdTSAhuPJR_NfOOTZS8F38mqLt5T2BVc6F0ptHmUHQtTi7xQUjxOd16IXMry-1H2LMYrzgvDdf00OyqMUVUtyuNsvrjGgL_mgDEO5Bl17HL_4bJgjvwShmZdMLKF2EwU2Bzo4CkOkYFvGfoevMOWORxHdgj0c-nZ4Fm_TpBOnGGh7WkdITAHwQ2eJniePelgjPjirp5k3z6efd1_zs8vPn3Zn57nrhRyyaGDRrlOaWHKtBJWHbaACBqVAmUACtF0EoXWpTTGtE2rODSu4xJAG1PJk-ztbd8U-seKcbHTELc44JHWaEUlS6UU5yqhr_9Dr2gNPqWzopaFNqouzQN1gBHt4DtaAritqT1Vplbc8KpO1Ju_qB5hXPpI47qkz43_gu9uQRcoxoCdncMwQbixgttNrKVgN7F2E5vwV3cZ12bC9h7-Y_JhcJyTnKGleM9QyKXOuc6lKrX8Dby2qq8</recordid><startdate>20161201</startdate><enddate>20161201</enddate><creator>Zhang, Xiubing</creator><creator>Hua, Lu</creator><creator>Yan, Daliang</creator><creator>Zhao, Fengbo</creator><creator>Liu, Jinxia</creator><creator>Zhou, Huiling</creator><creator>Liu, Jie</creator><creator>Wu, Miaomiao</creator><creator>Zhang, Chengliang</creator><creator>Chen, Yingying</creator><creator>Chen, Buyou</creator><creator>Hu, Baoying</creator><general>D.A. Spandidos</general><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20161201</creationdate><title>Overexpression of PCBP2 contributes to poor prognosis and enhanced cell growth in human hepatocellular carcinoma</title><author>Zhang, Xiubing ; Hua, Lu ; Yan, Daliang ; Zhao, Fengbo ; Liu, Jinxia ; Zhou, Huiling ; Liu, Jie ; Wu, Miaomiao ; Zhang, Chengliang ; Chen, Yingying ; Chen, Buyou ; Hu, Baoying</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c513t-afab4cf46175179e8fedaeea6e44a47aa21bf3e16653777dbd40abcf03aa67783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Alcohol</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Binding proteins</topic><topic>Cancer therapies</topic><topic>Carcinoma, Hepatocellular - metabolism</topic><topic>Carcinoma, Hepatocellular - mortality</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Care and treatment</topic><topic>Cell cycle</topic><topic>Cell growth</topic><topic>Cell Line, Tumor</topic><topic>Cell Proliferation</topic><topic>Chemotherapy</topic><topic>Development and progression</topic><topic>Drug resistance</topic><topic>Drug Resistance, Neoplasm</topic><topic>Female</topic><topic>Gene Expression</topic><topic>Genetic aspects</topic><topic>Health aspects</topic><topic>hepatocellular carcinoma</topic><topic>Hepatoma</topic><topic>Humans</topic><topic>Inhibitor drugs</topic><topic>Inhibitory Concentration 50</topic><topic>Kaplan-Meier Estimate</topic><topic>Liver cancer</topic><topic>Liver Neoplasms - metabolism</topic><topic>Liver Neoplasms - mortality</topic><topic>Liver Neoplasms - pathology</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Methods</topic><topic>Middle Aged</topic><topic>Molecular targeted therapy</topic><topic>Multivariate analysis</topic><topic>Niacinamide - analogs & derivatives</topic><topic>Niacinamide - pharmacology</topic><topic>Patients</topic><topic>Phenylurea Compounds - pharmacology</topic><topic>poly(C)-binding protein 2</topic><topic>Prognosis</topic><topic>Proteins</topic><topic>RNA-Binding Proteins - genetics</topic><topic>RNA-Binding Proteins - metabolism</topic><topic>sorafenib resistance</topic><topic>Surgery</topic><topic>Tumors</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Xiubing</creatorcontrib><creatorcontrib>Hua, Lu</creatorcontrib><creatorcontrib>Yan, Daliang</creatorcontrib><creatorcontrib>Zhao, Fengbo</creatorcontrib><creatorcontrib>Liu, Jinxia</creatorcontrib><creatorcontrib>Zhou, Huiling</creatorcontrib><creatorcontrib>Liu, Jie</creatorcontrib><creatorcontrib>Wu, Miaomiao</creatorcontrib><creatorcontrib>Zhang, Chengliang</creatorcontrib><creatorcontrib>Chen, Yingying</creatorcontrib><creatorcontrib>Chen, Buyou</creatorcontrib><creatorcontrib>Hu, Baoying</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Oncology reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Xiubing</au><au>Hua, Lu</au><au>Yan, Daliang</au><au>Zhao, Fengbo</au><au>Liu, Jinxia</au><au>Zhou, Huiling</au><au>Liu, Jie</au><au>Wu, Miaomiao</au><au>Zhang, Chengliang</au><au>Chen, Yingying</au><au>Chen, Buyou</au><au>Hu, Baoying</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Overexpression of PCBP2 contributes to poor prognosis and enhanced cell growth in human hepatocellular carcinoma</atitle><jtitle>Oncology reports</jtitle><addtitle>Oncol Rep</addtitle><date>2016-12-01</date><risdate>2016</risdate><volume>36</volume><issue>6</issue><spage>3456</spage><epage>3464</epage><pages>3456-3464</pages><issn>1021-335X</issn><eissn>1791-2431</eissn><abstract>Poly(C)-binding protein 2 (PCBP2) is a member of the PCBP family, and plays an important role in post-transcriptional and translational regulation of various signaling molecules through direct binding to single-stranded poly(C) motifs. PCBP2 has been reported to play a critical role in the development of multiple human tumors. However, whether PCBP2 participates in hepatocellular carcinoma (HCC) development remains largely elusive. Herein, we showed that PCBP2 was upregulated in human HCC tissues and cell lines. Overexpression of PCBP2 predicted significantly worsened prognosis in HCC patients, suggesting that PCBP2 may serve as a prognostic marker of HCC. In addition, we found that depletion of PCBP2 inhibited HCC cell proliferation, accompanying the increase in the cyclin-dependent kinase inhibitor p27 level. Moreover, we found that high expression of PCBP2 may contribute to sorafenib resistance in HCC cells, involving dysregulated expression of Bax and Bcl-2 proteins. In conclusion, our results suggest that PCBP2 may serve as a prognostic marker and potential therapeutic target of HCC.</abstract><cop>Greece</cop><pub>D.A. Spandidos</pub><pmid>27748915</pmid><doi>10.3892/or.2016.5167</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1021-335X |
| ispartof | Oncology reports, 2016-12, Vol.36 (6), p.3456-3464 |
| issn | 1021-335X 1791-2431 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1835444004 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adult Aged Alcohol Antineoplastic Agents - pharmacology Binding proteins Cancer therapies Carcinoma, Hepatocellular - metabolism Carcinoma, Hepatocellular - mortality Carcinoma, Hepatocellular - pathology Care and treatment Cell cycle Cell growth Cell Line, Tumor Cell Proliferation Chemotherapy Development and progression Drug resistance Drug Resistance, Neoplasm Female Gene Expression Genetic aspects Health aspects hepatocellular carcinoma Hepatoma Humans Inhibitor drugs Inhibitory Concentration 50 Kaplan-Meier Estimate Liver cancer Liver Neoplasms - metabolism Liver Neoplasms - mortality Liver Neoplasms - pathology Male Medical prognosis Metastasis Methods Middle Aged Molecular targeted therapy Multivariate analysis Niacinamide - analogs & derivatives Niacinamide - pharmacology Patients Phenylurea Compounds - pharmacology poly(C)-binding protein 2 Prognosis Proteins RNA-Binding Proteins - genetics RNA-Binding Proteins - metabolism sorafenib resistance Surgery Tumors Young Adult |
| title | Overexpression of PCBP2 contributes to poor prognosis and enhanced cell growth in human hepatocellular carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T16%3A18%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Overexpression%20of%20PCBP2%20contributes%20to%20poor%20prognosis%20and%20enhanced%20cell%20growth%20in%20human%20hepatocellular%20carcinoma&rft.jtitle=Oncology%20reports&rft.au=Zhang,%20Xiubing&rft.date=2016-12-01&rft.volume=36&rft.issue=6&rft.spage=3456&rft.epage=3464&rft.pages=3456-3464&rft.issn=1021-335X&rft.eissn=1791-2431&rft_id=info:doi/10.3892/or.2016.5167&rft_dat=%3Cgale_proqu%3EA479407089%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1932674957&rft_id=info:pmid/27748915&rft_galeid=A479407089&rfr_iscdi=true |